1. Introduction {#sec1}
===============

Cardiovascular complications are associated with diabetes and lead to high mortality \[[@B1], [@B2]\]. Diabetic cardiomyopathy (DCM) is one of the main causes of heart injury and death in patients with diabetes. A total of 1.6 million deaths worldwide are directly attributed to diabetes every year \[[@B3]\]. Independent of coronary artery disease, DCM has increased prevalence during the last two decades and is experienced by 55% of patients with diabetes \[[@B4]\]. With diabetes being a global epidemic, the number of patients with DCM has increased. For the last two decades, the number of people with diabetes worldwide has increased from 151 million in 2000 to 425 million in 2017 and is estimated to increase to 629 million by 2045 \[[@B5]\]. The risk of developing DCM is higher for patients with diabetes than that for those without diabetes \[[@B6]\] and increases 2 to 4 times for those with more than a 10-year span of diabetes \[[@B7], [@B8]\]. Once DCM has developed, reducing its morbidity and mortality is difficult even with pharmacological improvement in terms of regulating blood glucose and insulin sensitivity. Clinical and preclinical investigations have examined the complexity of the pathophysiological consequences of DCM.

Clinical studies in patients with DCM reported that the pathological remodeling of the heart, which is characterized by left ventricular concentric hypertrophy and perivascular and interstitial fibrosis commencing to diastolic dysfunction and extended contraction and relaxation \[[@B9], [@B10]\], shortens ventricular ejection and increases wall stiffness \[[@B11], [@B12]\]. The influence of the diabetic condition on heart and cardiomyocyte function has been experimentally evaluated.

DCM and cardiac dysfunction are initiated in diabetic-induced experimental animals from 2 to 12 weeks \[[@B13]\]. Streptozotocin-induced diabetes in mice leads to the morphological changes of heart tissues, interstitial collagen deposition, cardiac hypertrophy, fibrosis, and remarkable elevation of paracrine of angiotensin II level in myocardium and NADPH oxidase activities, which are considered the primary source of free radicals in the cardiomyocytes of diabetic heart \[[@B14]\]. Connective tissue growth factor mediates cardiac fibrosis in diabetes \[[@B13], [@B15]\]. In diabetic mice with cardiomyopathy, the expression of sarcoplasmic reticulum calcium ATPase and \[Ca^+2^\] ion transient is reduced \[[@B16]\]. Sarcoplasmic reticulum calcium ATPase is a primary cardiac isoform of calcium pump transporting calcium from cytoplasm to sarcoplasmic reticulum during diastolic relaxation \[[@B17]\].

Even with substantial advances in cardiovascular therapy, diabetic morbidity and mortality rate are continually increasing, and a feasible therapeutic approach for DCM is still lacking. Exploring the medication targets for DCM may further identify novel drugs and improve specific therapies for DCM. Therapeutic targets for DCM with natural resources are considered as one of the main reservoirs for drug discovery. Therefore, novel therapeutics for a range of targets must be developed to prevent DCM progression. This study identifies molecular target involvement and its association with DCM by using the Open Targets Platform (OTP) website established by Biogen, EMBL European Bioinformatics Institute, GlaxoSmithKline, and Wellcome Trust Sanger Institute. The OTP provides comprehensive and up-to-date data for drug molecular targets associated with relative diseases. Oxidative stress (OS) may be a key factor in the molecular and cellular mechanisms of diabetes-induced DCM \[[@B18]\]. Hence, targeting OS-related processes could be a promising therapeutic strategy for DCM.

*Ganoderma (G.) lucidum*, which is known in Chinese as "Lingzhi," is a medicinal mushroom commonly used as a Chinese herbal medicine and the main ingredient in many conventional combinations or dietary supplements \[[@B19]\]. This name has been proposed by Petter Adolf Karsten from England in the late 19^th^ century and has been applied in various places such as Asia, Africa, Oceania, and Europe \[[@B20]\]. Lingzhi has been widely cultivated in China and has a long history as a traditional Chinese medicine. Chinese *G. lucidum* exhibits high variability of basidioma morphology and more or less consistency in its microscopic characters, e.g., short clavate cutis elements, Bovista-type ligative hyphae, and strongly echinulated basidiospores \[[@B21]\]. *G. lucidum* also contains various bioactive compounds, such as flavonoids, ganoderic acid, phenolics, and polysaccharides \[[@B21]\], that can treat many chronic diseases including diabetes and its complications by counteracting OS. Preclinical studies reported the beneficial effects of *G. lucidum* against OS-induced diseases, its liver protection against CCl~4~-induced OS \[[@B22]\], skin protection against croton oil-induced lipid peroxidation in mice \[[@B23]\], and thymus and spleen protection against 5-fluorouracil-induced OS in mice \[[@B21]\]. This systematic review is aimed at discussing the potential cell targets and cardioprotective pathway of *G. lucidum* based on preclinical and clinical investigations.

2. Methods {#sec2}
==========

The OTP website version 19.11 (OTP V 19.11) was used to prioritize and identify the targets associated with DCM. The OTP provides score and rank target-disease associations and integrates evidence from six resources, including genetics, genomics, transcriptomics, drugs, animal models, and scientific literature \[[@B24], [@B25]\]. Two main steps of searching were performed in December 2019. In the first step, the term "diabetic cardiomyopathy" was used, and all the targets associated with DCM were listed according to available evidence recorded through bioinformatic processing, including data evidence of drug, text mining, genetic association, somatic mutation, pathways and signals, RNA signal, and animal model. The resulting targets with the highest association with DCM from the first step were used to further search for evidence on *G. lucidum* cardioprotection.

This systematic review on the antioxidant activity of *G. lucidum* was described as follows. Abstracts published from 1985 to July 2019 were reported as guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses \[[@B26]\] ([Figure 1](#fig1){ref-type="fig"}). The key terms used were *G. lucidum* and spore of *G. lucidum*. In this step, the studies were divided into seven 5-year periods to easily read and select related abstracts. The search was limited to studies published in English and Chinese languages. Inclusion criteria were as follows: studies must focus on (1) *G. lucidum* and its (2) antioxidant, antidiabetic, and cardioprotective activities. Exclusion criteria were as follows: studies focusing on (1) mushrooms other than *G. lucidum* and (2) not related to its antioxidant activities such as the botanical and genetic studies of *G. lucidum.*

3. Results {#sec3}
==========

3.1. Targets Associated with DCM in Diabetes Integrated by OTP {#sec3.1}
--------------------------------------------------------------

### 3.1.1. DCM and Its Associated Targets {#sec3.1.1}

A total of 309 targets were associated with DCM based on evidence from drug and text mining data with overall association scores from 0.004 to 0.177 ([Table 1](#tab1){ref-type="table"}, supplementary file (available [here](#supplementary-material-1){ref-type="supplementary-material"})). Among the selected drug data, only two targets, namely, carnitine palmitoyltransferase 1B (CPT1B) and 2 (CPT2) were associated with DCM with 0.1 score association. A total of 306 targets were identified from text mining. Only the mechanistic target of rapamycin kinase (mTOR) was common in both types of data. A total of 309 targets were expressed in 32 tissue organs including the heart and were involved in 19 pathway types ([Table 2](#tab2){ref-type="table"}, supplementary file (available [here](#supplementary-material-1){ref-type="supplementary-material"})). Among these 309 targets, 155 were expressed in the heart tissues with overall association scores ranging from 0.007 to 0.177 ([Table 1](#tab1){ref-type="table"}). Among the 19 pathways, 4 targets were included in autophagy ([Table 2](#tab2){ref-type="table"}), namely, mTOR, beclin 1 (BECN1), parkin RBR E3 ubiquitin protein ligase (PRKN), and voltage-dependent anion channel 1 (VDAC1) with scores of 0.1, 0.06, 0.05, and 0.03, respectively.

mTOR was further investigated, and its association with heart diseases ranged from 0.0004 to 0.8588, which is the overall association score for 49 subtypes of heart diseases. mTOR had 0.1 and 0.8 overall association scores with DCM and hypertrophic cardiomyopathy, respectively ([Table 3](#tab3){ref-type="table"}).

mTOR is a serine/threonine-protein kinase playing as a central regulator of cellular metabolism, growth, and survival in response to hormone growth factor \[[@B27]\], nutrients, energy, and stress signals \[[@B28], [@B29]\]. According to UniPort, mTOR can be found in different subcellular locations including the membranes of endoplasmic reticulum, Golgi apparatus, outer mitochondrion, microsome, and lysosome; lysosome, cytoplasm, nucleus, and PML nuclear body. The RNA and protein expression levels of mTOR are present in several organs including the heart, e.g., the medium RNA and high protein levels of mTOR are expressed in the left ventricle, atrium, and coronary artery but not in the heart muscles ([Figure 2](#fig2){ref-type="fig"}).

### 3.1.2. Evidence on the Cardioprotection of *G. lucidum* {#sec3.1.2}

A total of 1731 articles were identified ([Figure 3](#fig3){ref-type="fig"}) and further divided into seven 5-year time periods. The first period ranged from 1985 to 1989, and the last period ranged from August 2018 to August 2019 ([Figure 1](#fig1){ref-type="fig"}). These articles were reviewed in the following three phases. First, 1571 articles remained after the duplicated ones were removed. Second, articles that did not satisfy the inclusion criteria based solely on their titles (remaining 1399 articles) and abstracts (remaining 59 articles) were excluded. Lastly, the remaining articles were scanned, and those that did not meet our inclusion criteria were excluded. After the initial screening of titles and abstracts, the 59 remaining articles were screened for the second time by two individual reviewers. Inclusion of full articles was agreed upon by two reviewers prior to data extraction. Finally, 33 studies were considered eligible for the review ([Figure 2](#fig2){ref-type="fig"}). In this section, the collected pieces of evidence were divided into two main parts, namely, the in vivo antioxidant of *G. lucidum* (14 studies, [Table 4](#tab4){ref-type="table"}), in which the in vivo effect of antioxidant on the parameters related to OS was discussed, and the in vitro antioxidant of *G. lucidum* (19 studies, [Table 5](#tab5){ref-type="table"}), in which the in vitro effect of antioxidant activities and possible molecular mechanisms was elaborated.

3.2. *In Vivo* Antioxidant Activity and Protective Effect of *G. lucidum* {#sec3.2}
-------------------------------------------------------------------------

According to 10 in vivo experimental studies, *G. lucidum* has antioxidant activities and protects against OS through four main factors in different tissues, such as the heart, liver, thymus, spleen, eyes, and skeletal muscles, and by regulating chemical-level OS parameters in blood circulation ([Table 4](#tab4){ref-type="table"}). *G. lucidum* exhibits its antioxidant effects by increasing the antioxidant enzymes and inhibiting the enzymes involved in OS. *G. lucidum* also increases the activities of superoxide dismutase (SOD), glutathione-S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), mitochondrial succinate dehydrogenase (SDH), and Mn-SOD and reduces glutathione (GSH) levels. By contrast, *G. lucidum* decreases the activities of nitric oxide synthase (NOS), cytochrome P450 2E1 (CYP2E1), xanthine oxidase (XOD), and myeloperoxidase (MPO). *G. lucidum* also significantly decreases lipid peroxidation levels, advanced oxidation protein products (AOPPs), and malondialdehyde (MDA) levels.

The first factor is the four toxic substances, including CCl~4~-induced oxidative stress (OS) in the liver, croton oil produced OS in the skin through inflammation, N-methyl-N-nitrosourea (MNU) causing retinal photoreceptor cell lesions in the eyes, and 5-fluorouracil-induced OS in the thymus and spleen of mice. Oral administration of *G. lucidum* polysaccharides (GLPs) represses free radical lipid peroxidation induced by CCl~4~ to reduce the enzyme activities of NOS and CYP2E1. Significant inhibition of NOS and CYP2E1 activities and MDA and IL-1*β* levels was noted in liver tissues, and depleted levels of interleukin- (IL-) 1*β*, IL-18, IL-6, and tumor necrosis factor-*α* were found in serum. In CCl~4~-induced liver damage, highly reactive trichloromethyl free radicals are generated by the cytochrome P450 isozymes (P450s) of the endoplasmic reticulum \[[@B22]\]. Topical administration of *G. lucidum* ethanol extract inhibits the croton oil-induced lipid peroxidation in the skin of mice \[[@B23]\]. Ganoderma spore lipid (GSL) shows a protective effect on MNU-induced retina injury by inhibiting the related apoptosis to modulate the expression levels of Bax, Bcl-xl, and caspase-3 \[[@B30]\]. GLPs also exhibit an antioxidant effect in 5-fluorouracil-induced OS and improve SOD, an intracellular compound that protects against oxidative processes initiated by superoxide anion and GPx contents in the spleen and thymus of mice \[[@B31]\].

The second factor creates conditions in biological systems that can induce OS, such as exercise-like exhaustive swimming, which is OS induced in skeletal muscles, and a carotid artery ligation, which disturbs the flow-induced OS level of manganese-dependent superoxide dismutase (Mn-SOD) in blood vessels. GLPs show protective effects against comprehensive swimming-induced OS by improving the activities of antioxidant enzymes (SOD, GPx, and CAT) and decreasing the MDA levels in the skeletal muscle of mice \[[@B32]\]. Oral ganoderma triterpenoids (GTs) protect against disturbed flow-induced OS through carotid artery ligation, which leads to chronic OS and inflammation that are features of early atherogenesis in mice, and by preventing neointimal thickening 2 weeks after ligation. Early atherogenesis includes neointimal hyperplasia and endothelial dysfunction due to flow turbulence in the ligated artery as induced by OS. GTs alleviate OS and restore the atheroresistent status of endothelium by inhibiting endothelin-1 induction, von Willebrand factor, and monocyte chemoattractant protein-1 after 3-day ligation as atherogenic factors \[[@B33]\]. Inflammatory cytokines, OS-induced endothelial dysfunction, and chronic OS contribute to endothelial impairment and induces atherogenesis.

The third factor in OS includes diseases such as type II diabetes mellitus (DM) and cancer. In type II DM, the beneficial effects of *G. lucidum* on abnormal heart and testis and epididymal cells of rats with streptozotocin-induced type II DM were evaluated. GLPs improve the myocardial ultrastructure by reducing MDA, activating antioxidant enzymes (GSH-Px, CAT, SOD, and NO) in cardiac tissues, and reducing lipid peroxidation in type II DM rats \[[@B34]\]. *G. lucidum* spores protect the testis of rats with type II DM by substantially increasing the mitochondrial SDH and decreasing the activities of XOD and MPO \[[@B35]\]. *G. lucidum* spores protect epididymal cells and counteract their apoptosis that damages the mitochondria and disequilibrium of calcium homeostasis by reducing the amount of mitochondrial cytoplasm cytochrome C in type II DM rats \[[@B36]\]. GLP administration enhances the immunity and antioxidant activities in N-methyl-N9-nitro-nitrosoguanidine-induced gastric cancer in Wistar rats. GLP remarkably reduces the levels of serum IL-6 and TNF-*α* and increases the levels of serum IL-2, IL-4, and IL-10. In addition, GLP improves the levels of SOD, CAT, and GSH-Px in serum and gastric tissues \[[@B37]\].

The fourth factor involved in OS is aging. *G. lucidum* administration ameliorates the age-related decline of antioxidant status in aged mice, substantially elevates the activities of GST, Mn-SOD, GPx, and CAT, and reduces GSH. By contrast, lipid peroxidation, AOPP, and reactive oxygen species (ROS) are reduced \[[@B38]\] ([Table 4](#tab4){ref-type="table"}).

3.3. *In Vitro* Antioxidant of *G. lucidum* and Its Possible Pathway {#sec3.3}
--------------------------------------------------------------------

Chemical antioxidant tests consistently revealed the free radical scavenging activity of *G. lucidum*. Twelve studies reported the scavenging activity of *G. lucidum* for different free radicals including 2,2-diphenylpicrylhydrazyl radical (DPPH^·^), 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS^·^+), hydroxyl radical (HO^·^), and hydrogen peroxide radicals (H~2~O~2~) \[[@B39]--[@B49]\] ([Table 5](#tab5){ref-type="table"}). *G. lucidum* also inhibits lipid peroxidation \[[@B23], [@B49]\]. In some studies, *G. lucidum* protects against DNA damage \[[@B41], [@B42], [@B50]\]. The results of chemical antioxidant tests regarding the antioxidant properties of *G. lucidum* are also in agreement with the cell-based antioxidant assays. *G. lucidum* shows free radical scavenging activity for H~2~O~2~ in RAW264.7 cells incubated with *G. lucidum* lipopolysaccharide and protects against H~2~O~2~-induced cell death \[[@B48]\]. *G. lucidum* also hinders sphingomyelinase activity in incubated RAW264.7 cells with lipopolysaccharide \[[@B51]\]. In addition, *G. lucidum* prevents lipid peroxidation in two cell models, namely, WBCs incubated with lipopolysaccharide to induce OS \[[@B39]\] and hepatocytes incubated with CCl~4~ to induce OS \[[@B52]\]. In both cell models, *G. lucidum* showed protection by elevating the antioxidant enzyme activity (SOD, GPx, and GR) and improving the GSH level. Moreover, *G. lucidum* protects macrophages in human monocytic cells incubated with lipopolysaccharide to stimulate NO production \[[@B53]\].

Wnt, Erk1/2, and NF-*κ*B are the possible signaling pathways of *G*. *lucidum* that support its antioxidant and protective effects. A pancreatic cell study suggested *β*-catenin in the Wnt signaling pathway as a target of ganoderic acid A, thus leading to cell protection and effective scavenging of ROS \[[@B54]\]. The Wnt signaling pathways transfer the signals from extracellular to intercellular and are stimulated by the Wnt protein binding to the cytoplasmic family receptor, which occurs in downstream cell signaling and controls the transcription of genes. In the canonical Wnt pathway, *β*-catenin accumulates in the cytoplasm and is further translocated into the nucleus, and this phenomenon is widely recognized as a regulation marker of fat and glucose metabolism and *β*-catenin/Wnt signaling involved in insulin secretion \[[@B54]\]. In 2006, Thyagarajan and his colleagues mentioned that *G. lucidum* modulates Erk1/2 signaling and transcription factors AP-1 and NF-*κ*B and downregulates c-Fos, whose expression can be induced by OS as the result of the inhibited OS-induced invasive behavior of breast cancer cells. A high H~2~O~2~ concentration (5 mM) can stimulate Erk1/2 signaling in MCF-7 cells \[[@B55]\].

In addition to its antioxidant activities, *G. lucidum* also exhibits an anti-inflammatory property and modulates the immune system. It can reverse LPS-induced inflammation by downregulating inflammatory mediators such as NF-*κ*B, thus substantially inhibiting NOS and reducing NO level \[[@B39]\]. *G. lucidum* also modulates the immune system byregulating cytokine production in RAW264.7 macrophages \[[@B56], [@B57]\]. Moreover, it increases the formation of autophagosomes and controls proteins (Vps34, beclin 1, LC3-I, LC3-II, and p62) that induce autophagy in a gastric adenocarcinoma cell line. *G. lucidum* increases the cellular levels of LC3-II and decreases the cellular levels of p62 ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

Among the 155 targets associated with DCM, mTOR, CPT1B, and CPT2 have the highest association. mTOR acts as a core regulator of cellular metabolism, growth, and survival in response to hormone growth factors, nutrients, energy, and stress signals. An animal study confirmed that streptozotocin-induced diabetes increases mTOR levels in rats \[[@B58]\]. mTOR can be found in different cellular locations including membrane, cytoplasm, and nucleus and different cellular organs (mitochondria, Golgi, and endoplasmic reticulum) and therefore is involved directly or indirectly in regulating the phosphorylation of at least 800 proteins (OPT.V19.11). mTOR functions through two distinct signaling complexes of mTORC1 and mTORC2 \[[@B59]\]. When activated, mTORC1 upregulates protein synthesis by phosphorylating the key regulators of mRNA translation and ribosome synthesis. mTORC1 also regulates protein synthesis \[[@B29]\], lipid synthesis \[[@B60]\], and mitochondrial biogenesis and stimulates the pyrimidine biosynthesis pathway through acute and delayed regulations. In acute regulation, mTORC1 stimulates pyrimidine biosynthesis through the ribosomal protein S6 kinase B1-mediated phosphorylation of biosynthetic enzyme carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase; these enzymes catalyze the first three steps in de novo pyrimidine synthesis \[[@B61]\]. In delayed regulation, mTORC1 stimulates pyrimidine biosynthesis through the transcriptional enhancement of the pentose phosphate pathway, which produces 5-phosphoribosyl-1-pyrophosphate, an allosteric activator of pyrimidine biosynthesis enzyme at a later step in the synthesis. In addition, mTORC1 regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through the phosphorylation and inhibition of MAF1 protein, a RNA polymerase III-repressor. When nutrients are available and mTOR kinase is active, MAF1 is hyperphosphorylated, and RNA polymerase III is engaged in the transcription \[[@B62]\]. Stress-induced MAF1 dephosphorylation resulted in nuclear localization, increased targeting of gene-bound RNA polymerase III, and decreased transcriptional readout \[[@B63], [@B64]\]. Moreover, mTORC1 is involved in the negative feedback regulation of autophagy on upstream growth factor signaling during microtubule regulation \[[@B64]--[@B66]\].

mTORC2 regulates other cellular processes such as survival and organization of cytoskeleton, actin cytoskeleton \[[@B67]\], osteoclastogenesis, and circadian clock function. In a pressure-overloaded male mouse heart, mTORC2 maintains a contractile function \[[@B68]\]. In brown adipose tissues, mTOR complex 2 has a role in *β*3-adrenoceptor-stimulated glucose uptake by stimulating the translocation of newly synthesized GLUT1 to the plasma membrane, thereby increasing the glucose uptake \[[@B69]\]. mTOR complex 2 regulates the proper turnover of insulin receptor substrate-1 \[[@B70]\].

*G. lucidum* exhibits cardiac protection via its antioxidant properties through OS modulation. This systemic review of 33 studies has documented its antioxidant activities. At the molecular and cellular levels, OS is a key in diabetes-induced DCM \[[@B18]\]. The antioxidant effects of *G. lucidum* are facilitated by increasing the antioxidant enzymes and inhibiting the enzymes involved in OS \[[@B33]--[@B35], [@B38]\]. *G. lucidum* consistently shows free radical scavenging activity against several free radicals including DPPH^·^, ABTS^·^+, HO^·^, and H~2~O~2~. As confirmed by the *in vitro* (chemical and cell-based) antioxidant tests, *G. lucidum* inhibits lipid peroxidation and protects against DNA damage.

*G. lucidum* modulates several signal pathways including Erk1/2, NF-*κ*B, and Wnt. Its antioxidant activity protects against inflammation and directly modulates immunity through scavenging radicals and through the oxidative signal pathways, thereby protecting the cells. These effects of *G. lucidum* may contribute to its positive influence on DCM.

DM is a state of persistent inflammation that upregulates mTOR at different levels of the myocardium, thereby influencing several signal pathways. The elevation of cellular cAMP levels disrupts phosphodiesterase-Rheb interaction, increases Rheb-mTOR interaction, and consequently leads to mTOR1 activation. Phosphodiesterase binds with Rheb and thereby inhibits the latter\'s ability to activate mTOR \[[@B71]\]. Heart myocardium responds to high blood glucose by adapting its energy metabolism and using only fatty acids as a substrate, thus increasing OS through the upregulation of NADPH-oxidases, NO synthases \[[@B72]\], and reversible oxidative modifications for myocardial titin elastic protein \[[@B73]\]. mTOR upregulation and oxidative modification alter titin-based stiffness and titin isoform composition, thereby impairing myocardium contractility. The PI3K-Akt-mTOR kinase axis regulates the composition of titin isoform \[[@B73]\]. OS decreases NO levels, leading to the impairment of the NO-soluble guanylate cyclase- (sGC-) cyclic guanosine monophosphate- (cGMP-) protein kinase G (PKG) pathway, an important regulator of cardiac contractility \[[@B72]\]. Chronic intrude accumulation to high free fatty acids downregulates PPAR-*α* and impairs mTOR-PPAR-*α*, thereby causing mitochondrial dysfunction in rodent cardiomyocytes and further deteriorating cardiac function through the inhibition of fatty acid oxidation and increase in intracellular fat accumulation. PPAR-*α* is involved in the upregulation of carnitine palmitoyltransferase I, which increases the uptake of long-chain fatty acid in the mitochondria and facilitates the beta-oxidation of fatty acids. mTOR-PPAR-*α* axis modification can lead to inflammation \[[@B74]\] and immune dysfunction \[[@B75]\]. mTOR upregulation leads to the impaired response to adrenergic stimulation in DCM mice and further reduces heart contractility \[[@B58]\]. mTOR inhibition improves contractility via the chronic administration of PDE inhibitor in animals and patients with diabetes \[[@B76]\] and restores the impaired response to adrenergic stimulation in DCM mice \[[@B58]\]. *G. lucidum* shows its effects via several signal pathways such as Wnt, Erk1/2, and NF-*κ*B pathway and consequently reduces the upregulated mTOR and its effects. mTOR is the main target of *G. lucidum*, and this finding supports its antioxidant and cardioprotective effects. *G. lucidum* inhibits the Wnt pathway \[[@B54]\] and may decrease the activity of mTOR via the Wnt/GSk/mTOR signal pathway. A pathologically stressed heart reactivates the Wnt signal pathway, which is modulated during left ventricular remodeling \[[@B77]\]. In heart cells, the Wnt pathway plays a role in the release of intracellular Ca^2+^ whose accumulation activates several Ca^+2^-sensitive proteins, fat and glucose metabolism, and cell fate decisions, such as renewal, differentiation, and apoptosis. Wnt dysregulation has an important role in cardiac diseases such as hypertrophy and fibrosis \[[@B78]\]. The Wnt pathway is important in the response to heart injuries leading to adverse effects on the heart \[[@B79]\] and is integrated with bioenergetic status to control mTOR activity \[[@B80]\]. Wnt is activated in late-stage inflammation of heart tissue \[[@B81]\]. *G. lucidum* suppresses Erk1/2 signaling \[[@B55]\] and consequently reduces the mTOR level. Erk1/2 signaling inhibits the TSC1/2 complex, which is the downregulator of mTOR, and thus activates mTOR \[[@B82]\]. The antioxidant properties of *G. lucidum* abolish the activation of the Erk pathway by OS. NADPH oxidase 2 is involved in Erk activation \[[@B83]\], and the inhibition of Erk/mTOR by *G. lucidum* also prevents NF-*κ*B. mTOR activates NF-*κ*B by phosphorylating the NF-*κ*B p65 subunit, increasing p65 nuclear translocation, and activating gene transcription. With its anti-inflammatory effect, *G. lucidum* inhibits NF-*κ*B via decreasing inflammatory mediators and cytokines such as TNF or IL-1, and innate immune response effectors activate NF-*κ*B via the IKK complex through I*κ*B protein phosphorylation with subsequent ubiquitination and degradation \[[@B84]\]. Inhibiting mTOR and NF-*κ*B may improve the contractility of the heart, abolish the angiotensin II-induced hypertrophic response of cardiomyocytes \[[@B83]\], and prevent heart failure. A prolonged NF-*κ*B activation promotes heart failure by evoking signals that induce chronic inflammation through the enhancement of cytokines including tumor necrosis factor, IL-1, and IL-6, commencing to endoplasmic reticulum stress responses and cell death \[[@B85]\].

Our results concluded that the antioxidant properties of *G. lucidum* and the cardioprotection of its polysaccharides may have a direct effect. Its free radical scavenging ability reduces OS and upregulates mTOR via several pathways including Wnt, Erk1/2, and NF-*κ*B/IKK/TOR, thereby improving myocardium contractility ([Figure 4](#fig4){ref-type="fig"}). The anti-inflammatory properties may enhance the cAMP/cGMP/mTOR/PPAR pathway and its related protein or/and pathway and mitochondrial function, thus improving myocardium hemostasis. Further study is needed to identify the specific target of GLP in heart tissues.

This research was funded by the Jiamusi University, Basic Medicine College team, under grant number JDXKTD-2019002.
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Supplementary Table 1: association sore of 309 targets associated with diabetic cardiomyopathy in 30 recorded tissues. Supplementary Table 2: thirty-two tissue organs expressed 309 targets and types of pathways.
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![A PRISMA flow diagram summarising the study selection process. Antioxidant of *G. Lucidum*; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses. ^∗^After exclusion of other antioxidant activity studies of *G. Lucidum.*](BMRI2020-7136075.001){#fig1}

![mRNA and protein baseline expression of mTOR in the heart.](BMRI2020-7136075.002){#fig2}

![Number of studies on *G*. *lucidum* during 1985-2019.](BMRI2020-7136075.003){#fig3}

![*G. lucidum* inhibits mTOR via several signal pathways (- inhibit; + stimulate). Red +/- effects of inflammation, glucose starvation and fat metabolism, and oxidative stress on different effectors of different pathways in cardiocytes; black +/- protective effects of *G lucidum* at different effectors of different pathways in cardiocytes.](BMRI2020-7136075.004){#fig4}

###### 

Association sore of 155 targets associated with diabetic cardiomyopathy in heart tissue.

        Target name                                                       Target symbol   Association score           
  ----- ----------------------------------------------------------------- --------------- ------------------- ------- -------
  1     Tripartite motif containing 55                                    TRIM55          0                   0.177   0.177
  2     Peroxisome proliferator-activated receptor alpha                  PPARA           0                   0.117   0.117
  3     Mechanistic target of rapamycin kinase                            MTOR            0.1                 0.054   0.113
  4     Interleukin 6                                                     IL-6            0                   0.113   0.113
  5     Carnitine palmitoyltransferase 1B                                 CPT1B           0.1                 0.000   0.100
  6     Carnitine palmitoyltransferase 2                                  CPT2            0.1                 0.000   0.100
  7     Tripartite motif containing 54                                    TRIM54          0                   0.081   0.081
  8     Nuclear factor, erythroid 2 like 2                                NFE2L2          0                   0.072   0.072
  9     Hydroxysteroid 11-beta dehydrogenase 1                            HSD11B1         0                   0.070   0.070
  10    Fibroblast growth factor 1                                        FGF1            0                   0.070   0.070
  11    Colony-stimulating factor 3                                       CSF3            0                   0.062   0.062
  12    Beclin 1                                                          BECN1           0                   0.062   0.062
  13    Cytochrome P450 family 2 subfamily J member 2                     CYP2J2          0                   0.061   0.061
  14    Angiotensin I-converting enzyme 2                                 ACE2            0                   0.060   0.060
  15    Aldehyde dehydrogenase 2 family member                            ALDH2           0                   0.059   0.059
  16    Glycogen synthase kinase 3 beta                                   GSK3B           0                   0.057   0.057
  17    Gelsolin                                                          GSN             0                   0.055   0.055
  18    Toll-like receptor 2                                              TLR2            0                   0.054   0.054
  19    Parkin RBR E3 ubiquitin protein ligase                            PRKN            0                   0.054   0.054
  20    Apelin                                                            APLN            0                   0.053   0.053
  21    ST3 beta-galactoside alpha-2,3-sialyltransferase 4                ST3GAL4         0                   0.052   0.052
  22    Peroxisome proliferator activated receptor gamma                  PPARG           0                   0.052   0.052
  23    Corin, serine peptidase                                           CORIN           0                   0.052   0.052
  24    Titin                                                             TTN             0                   0.049   0.049
  25    Angiogenin                                                        ANG             0                   0.049   0.049
  26    Protein kinase D1                                                 PRKD1           0                   0.049   0.049
  27    PPARG coactivator 1 alpha                                         PPARGC1A        0                   0.048   0.048
  28    Vascular endothelial growth factor A                              VEGFA           0                   0.048   0.048
  29    Insulin-like growth factor 1                                      IGF1            0                   0.047   0.047
  30    CD36 molecule                                                     CD36            0                   0.047   0.047
  31    Nitric oxide synthase 3                                           NOS3            0                   0.046   0.046
  32    Apolipoprotein A1                                                 APOA1           0                   0.044   0.044
  33    Gap junction protein alpha 1                                      GJA1            0                   0.041   0.041
  34    Calsequestrin 2                                                   CASQ2           0                   0.041   0.041
  35    Decorin                                                           DCN             0                   0.040   0.040
  36    Urocortin                                                         UCN             0                   0.040   0.040
  37    Cellular communication network factor 2                           CCN2            0                   0.040   0.040
  38    Matrix metallopeptidase 2                                         MMP2            0                   0.040   0.040
  39    Periostin                                                         POSTN           0                   0.039   0.039
  40    Fibroblast growth factor 2                                        FGF2            0                   0.039   0.039
  41    BCL6 transcription repressor                                      BCL6            0                   0.039   0.039
  42    Tax1-binding protein 1                                            TAX1BP1         0                   0.038   0.038
  43    Solute carrier family 2 member 4                                  SLC2A4          0                   0.038   0.038
  44    Rho-associated coiled-coil containing protein kinase 2            ROCK2           0                   0.037   0.037
  45    NADPH oxidase 4                                                   NOX4            0                   0.036   0.036
  46    Mitogen-activated protein kinase 9                                MAPK9           0                   0.036   0.036
  47    Insulin-like growth factor 2                                      IGF2            0                   0.036   0.036
  48    Angiotensin II receptor type 2                                    AGTR2           0                   0.036   0.036
  49    Lipoprotein lipase                                                LPL             0                   0.036   0.036
  50    Insulin receptor                                                  INSR            0                   0.035   0.035
  51    Angiopoietin 1                                                    ANGPT1          0                   0.035   0.035
  52    Interleukin 33                                                    IL33            0                   0.035   0.035
  53    Caveolin 3                                                        CAV3            0                   0.034   0.034
  54    Angiotensin I-converting enzyme                                   ACE             0                   0.034   0.034
  55    Patatin-like phospholipase domain containing 2                    PNPLA2          0                   0.034   0.034
  56    ATPase sarcoplasmic/endoplasmic reticulum Ca^2+^ transporting 2   ATP2A2          0                   0.033   0.033
  57    Glucokinase                                                       GCK             0                   0.032   0.032
  58    Dimethylarginine dimethylaminohydrolase 2                         DDAH2           0                   0.032   0.032
  59    Xenotropic and polytropic retrovirus receptor 1                   XPR1            0                   0.032   0.032
  60    Vascular endothelial growth factor B                              VEGFB           0                   0.032   0.032
  61    Phosphodiesterase 5A                                              PDE5A           0                   0.031   0.031
  62    MAPK-activated protein kinase 2                                   MAPKAPK2        0                   0.031   0.031
  63    Heat shock protein family E (Hsp10) member 1                      HSPE1           0                   0.031   0.031
  64    Sirtuin 2                                                         SIRT2           0                   0.031   0.031
  65    DIRAS family GTPase 3                                             DIRAS3          0                   0.030   0.030
  66    SMAD family member 3                                              SMAD3           0                   0.030   0.030
  67    Dual specificity phosphatase 5                                    DUSP5           0                   0.030   0.030
  68    Kruppel-like factor 4                                             KLF4            0                   0.030   0.030
  69    Ryanodine receptor 2                                              RYR2            0                   0.029   0.029
  70    Prohibitin                                                        PHB             0                   0.029   0.029
  71    Estrogen related receptor gamma                                   ESRRG           0                   0.028   0.028
  72    Nebulin                                                           NEB             0                   0.028   0.028
  73    Peroxiredoxin 3                                                   PRDX3           0                   0.028   0.028
  74    Adrenoceptor beta 2                                               ADRB2           0                   0.028   0.028
  75    Solute carrier family 9 member A1                                 SLC9A1          0                   0.028   0.028
  76    Transglutaminase 2                                                TGM2            0                   0.027   0.027
  77    Poly(ADP-ribose) polymerase 1                                     PARP1           0                   0.027   0.027
  78    Insulin receptor substrate 1                                      IRS1            0                   0.027   0.027
  79    Voltage dependent anion channel 1                                 VDAC1           0                   0.026   0.026
  80    AKT serine/threonine kinase 1                                     AKT1            0                   0.025   0.025
  81    Myocyte enhancer factor 2A                                        MEF2A           0                   0.025   0.025
  82    Dual specificity phosphatase 1                                    DUSP1           0                   0.025   0.025
  83    Musculin                                                          MSC             0                   0.025   0.025
  84    Diacylglycerol kinase zeta                                        DGKZ            0                   0.024   0.024
  85    Death associated protein kinase 2                                 DAPK2           0                   0.024   0.024
  86    Solute carrier family 25 member 4                                 SLC25A4         0                   0.023   0.023
  87    SMAD family member 7                                              SMAD7           0                   0.023   0.023
  88    Natriuretic peptide A                                             NPPA            0                   0.023   0.023
  89    Coiled-coil domain containing 47                                  CCDC47          0                   0.022   0.022
  90    Lipase E, hormone sensitive type                                  LIPE            0                   0.022   0.022
  91    Leptin                                                            LEP             0                   0.022   0.022
  92    Arylsulfatase A                                                   ARSA            0                   0.021   0.021
  93    Nitric oxide synthase 2                                           NOS2            0                   0.021   0.021
  94    Nuclear receptor subfamily 3 group C member 2                     NR3C2           0                   0.021   0.021
  95    Sirtuin 3                                                         SIRT3           0                   0.021   0.021
  96    Plasminogen                                                       PLG             0                   0.020   0.020
  97    Spindlin 1                                                        SPIN1           0                   0.020   0.020
  98    Serpin family E member 1                                          SERPINE1        0                   0.020   0.020
  99    Tachykinin receptor 1                                             TACR1           0                   0.020   0.020
  100   RNA binding fox-1 homolog 2                                       RBFOX2          0                   0.020   0.020
  101   Fatty acid binding protein 4                                      FABP4           0                   0.019   0.019
  102   Potassium voltage-gated channel subfamily H member 2              KCNH2           0                   0.019   0.019
  103   Cell adhesion molecule 1                                          CADM1           0                   0.019   0.019
  104   Prolylcarboxypeptidase                                            PRCP            0                   0.018   0.018
  105   Nucleotide-binding oligomerization domain containing 1            NOD1            0                   0.018   0.018
  106   Activating transcription factor 3                                 ATF3            0                   0.018   0.018
  107   Vasoactive intestinal peptide                                     VIP             0                   0.018   0.018
  108   Egl-9 family hypoxia inducible factor 3                           EGLN3           0                   0.018   0.018
  109   Fibronectin 1                                                     FN1             0                   0.018   0.018
  110   Endothelin 1                                                      EDN1            0                   0.018   0.018
  111   C-C motif chemokine ligand 2                                      CCL2            0                   0.018   0.018
  112   Solute carrier family 5 member 1                                  SLC5A1          0                   0.018   0.018
  113   Fibrinogen-like 2                                                 FGL2            0                   0.017   0.017
  114   Monoamine oxidase A                                               MAOA            0                   0.017   0.017
  115   Sphingosine-1-phosphate receptor 1                                S1PR1           0                   0.017   0.017
  116   Signal transducer and activator of transcription 3                STAT3           0                   0.017   0.017
  117   Toll-like receptor 3                                              TLR3            0                   0.017   0.017
  118   Tripartite motif containing 63                                    TRIM63          0                   0.017   0.017
  119   TIMP metallopeptidase inhibitor 2                                 TIMP2           0                   0.017   0.017
  120   Nerve growth factor                                               NGF             0                   0.017   0.017
  121   Natriuretic peptide receptor 2                                    NPR2            0                   0.016   0.016
  122   Cyclin-dependent kinase inhibitor 1A                              CDKN1A          0                   0.016   0.016
  123   Cathepsin D                                                       CTSD            0                   0.016   0.016
  124   Thrombospondin 1                                                  THBS1           0                   0.015   0.015
  125   Kinase insert domain receptor                                     KDR             0                   0.015   0.015
  126   Serine/threonine kinase 11                                        STK11           0                   0.015   0.015
  127   Enolase 3                                                         ENO3            0                   0.015   0.015
  128   Gasdermin D                                                       GSDMD           0                   0.015   0.015
  129   Cytochrome c, somatic                                             CYCS            0                   0.015   0.015
  130   Kallikrein B1                                                     KLKB1           0                   0.015   0.015
  131   TIMP metallopeptidase inhibitor 4                                 TIMP4           0                   0.015   0.015
  132   Transforming growth factor beta 3                                 TGFB3           0                   0.015   0.015
  133   Zinc finger and BTB domain containing 16                          ZBTB16          0                   0.015   0.015
  134   Collagen type I alpha 1 chain                                     COL1A1          0                   0.015   0.015
  135   Endothelin receptor type A                                        EDNRA           0                   0.014   0.014
  136   Cellular communication network factor 1                           CCN1            0                   0.014   0.014
  137   Secreted protein acidic and cysteine rich                         SPARC           0                   0.014   0.014
  138   Glucagon like peptide 1 receptor                                  GLP1R           0                   0.014   0.014
  139   Cystatin C                                                        CST3            0                   0.014   0.014
  140   Intercellular adhesion molecule 1                                 ICAM1           0                   0.014   0.014
  141   Elastin                                                           ELN             0                   0.014   0.014
  142   Tenascin C                                                        TNC             0                   0.014   0.014
  143   PTEN-induced kinase 1                                             PINK1           0                   0.014   0.014
  144   Calpastatin                                                       CAST            0                   0.014   0.014
  145   CCAAT enhancer binding protein beta                               CEBPB           0                   0.012   0.012
  146   Acyl-coA thioesterase 1                                           ACOT1           0                   0.012   0.012
  147   G protein-coupled bile acid receptor 1                            GPBAR1          0                   0.010   0.010
  148   Annexin A1                                                        ANXA1           0                   0.010   0.010
  149   Apolipoprotein L2                                                 APOL2           0                   0.008   0.008
  150   Natriuretic peptide B                                             NPPB            0                   0.008   0.008
  151   Leptin receptor                                                   LEPR            0                   0.008   0.008
  152   Serum response factor                                             SRF             0                   0.008   0.008
  153   Heat shock protein family B (small) member 3                      HSPB3           0                   0.007   0.007
  154   Angiotensin II receptor type 1                                    AGTR1           0                   0.007   0.007
  155   Protein phosphatase 5 catalytic subunit                           PPP5C           0                   0.007   0.007

###### 

Nineteen pathway types involved in the heart tissues of 155 targets expressed.

  No.    Pathway (No. of targets)
  ------ ---------------------------------------------
  1\.    Signal transduction (63)
  2\.    Immune system (47)
  3\.    Metabolism of proteins (39)
  4\.    Metabolism (31)
  5\.    Gene expression (transcription) (25)
  6\.    Hemostasis (23)
  7\.    Disease (22)
  8\.    Developmental biology (20)
  9\.    Extracellular matrix organization (18)
  10\.   Cellular responses to external stimuli (14)
  11\.   Transport of small molecules (11)
  12\.   Muscle contraction (11)
  13\.   Vesicle-mediated transport (10)
  14\.   Organelle biogenesis and maintenance (4)
  15\.   Programmed cell death (4)
  16\.   Autophagy (4)
  17\.   Neuronal system (3)
  18\.   Cell cycle (3)
  19\.   Circadian clock (3)

###### 

mTOR score association with 49 heart diseases.

  No.   Heart disease                                             Association score                                 
  ----- --------------------------------------------------------- ------------------- --------- --------- --------- --------
  1     Heart disease                                             0.00041             0.79550   0.14161   0.19028   0.8588
  2     Cardiomyopathy                                            0.00000             0.77847   0.11930   0.19028   0.8393
  3     Hypertrophic cardiomyopathy                               0.00000             0.77222   0.10214   0.00000   0.7978
  4     Heart failure                                             0.00000             0.25000   0.05235   0.00000   0.2631
  5     Dilated cardiomyopathy                                    0.00000             0.00000   0.07568   0.19028   0.2092
  6     Congestive heart failure                                  0.00000             0.20000   0.02636   0.00000   0.2066
  7     Diastolic heart failure                                   0.00000             0.20000   0.00000   0.00000   0.2000
  8     Barth syndrome                                            0.00000             0.00000   0.00000   0.19028   0.1903
  9     Coronary heart disease                                    0.00000             0.00000   0.12009   0.00000   0.1201
  10    Diabetic cardiomyopathy                                   0.00000             0.10000   0.05391   0.00000   0.1135
  11    Coronary artery disease                                   0.00000             0.00000   0.10961   0.00000   0.1096
  12    Systemic scleroderma                                      0.00000             0.00000   0.09914   0.00000   0.0991
  13    Cardiotoxicity                                            0.00000             0.00000   0.09016   0.00000   0.0902
  14    Glycogen storage disease due to acid maltase deficiency   0.00000             0.00000   0.08380   0.00000   0.0838
  15    Myocardial infarction                                     0.00000             0.00000   0.06467   0.00000   0.0647
  16    Persistent truncus arteriosus                             0.00000             0.00000   0.06144   0.00000   0.0614
  17    Heart neoplasm                                            0.00000             0.00000   0.06126   0.00000   0.0613
  18    Emery-Dreifuss muscular dystrophy                         0.00000             0.00000   0.05780   0.00000   0.0578
  19    Ischemia reperfusion injury                               0.00000             0.00000   0.05702   0.00000   0.0570
  20    Myocardial ischemia                                       0.00000             0.00000   0.05658   0.00000   0.0566
  21    Carney complex                                            0.00000             0.00000   0.05494   0.00000   0.0549
  22    Down syndrome                                             0.00000             0.00000   0.05488   0.00000   0.0549
  23    Cardiac rhabdomyoma                                       0.00000             0.00000   0.05475   0.00000   0.0547
  24    Autosomal dominant Emery-Dreifuss muscular dystrophy      0.00000             0.00000   0.05280   0.00000   0.0528
  25    Polyarteritis nodosa                                      0.00000             0.00000   0.04343   0.00000   0.0434
  26    Steinert myotonic dystrophy                               0.00000             0.00000   0.04273   0.00000   0.0427
  27    Acute myocardial infarction                               0.00000             0.00000   0.03798   0.00000   0.0380
  28    Cardiac arrhythmia                                        0.00041             0.00000   0.03721   0.00000   0.0373
  29    Myocarditis                                               0.00000             0.00000   0.03263   0.00000   0.0326
  30    Duchenne muscular dystrophy                               0.00000             0.00000   0.03253   0.00000   0.0325
  31    Gaucher disease                                           0.00000             0.00000   0.03230   0.00000   0.0323
  32    Cardiac arrest                                            0.00000             0.00000   0.02847   0.00000   0.0285
  33    Atrial fibrillation                                       0.00000             0.00000   0.02720   0.00000   0.0272
  34    Aortic stenosis                                           0.00000             0.00000   0.01910   0.00000   0.0191
  35    Acute coronary syndrome                                   0.00000             0.00000   0.01900   0.00000   0.0190
  36    Sleep disorder                                            0.00000             0.00000   0.01840   0.00000   0.0184
  37    Williams syndrome                                         0.00000             0.00000   0.01640   0.00000   0.0164
  38    Supravalvular aortic stenosis                             0.00000             0.00000   0.01640   0.00000   0.0164
  39    Autoimmune myocarditis                                    0.00000             0.00000   0.01560   0.00000   0.0156
  40    Friedreich ataxia                                         0.00000             0.00000   0.01480   0.00000   0.0148
  41    Obstructive sleep apnea                                   0.00000             0.00000   0.01480   0.00000   0.0148
  42    PHACE syndrome                                            0.00000             0.00000   0.01440   0.00000   0.0144
  43    Glycogen storage disease due to LAMP-2 deficiency         0.00000             0.00000   0.01440   0.00000   0.0144
  44    Idiopathic pulmonary arterial hypertension                0.00000             0.00000   0.01400   0.00000   0.0140
  45    Fabry disease                                             0.00000             0.00000   0.01340   0.00000   0.0134
  46    Becker muscular dystrophy                                 0.00000             0.00000   0.00840   0.00000   0.0084
  47    Hemopericardium                                           0.00000             0.00000   0.00720   0.00000   0.0072
  48    Aortic coarctation                                        0.00000             0.00000   0.00680   0.00000   0.0068
  49    Atrial flutter                                            0.00041             0.00000   0.00000   0.00000   0.0004

###### 

*In vivo* studies of *G. lucidum.*

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Animal                                                                                 Form                                                                                                                              Dosage (mg/kg)                                           Antioxidant parameters                                                                                               Biological activity                                                 Pathway                                                                                                                                                                                                                                                                    References
  ----- -------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  1     CCl~4~-induced acute liver injury mice                                                 GLPS                                                                                                                              100 - 150                                                NOS CYP2E1 MDA, GSH                                                                                                  Suppressing free radical lipid peroxidation                         Decreasing of the protein expression levels of NLRP3, ASC, and caspase-1 in acute liver injury.\                                                                                                                                                                           \[[@B22]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ASC (apoptosis-associated speck-like protein)\                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   NLRP3 (NOD-like receptor 3)\                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Caspase-1\                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   GAPDH (glyceraldehyde-3-phosphate hydrogenase                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  2     Croton oil applied skin edema in rats                                                  Ethanol extract of sporocarps                                                                                                     500 and 1000 mg/kg                                                                                                                                                            Antiperoxidative, anti-inflammatory, and antimutagenic activities   Direct anti-inflammatory and free radical scavenging properties of the extract                                                                                                                                                                                             \[[@B23]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  3     Photoreceptor cell lesions induced by N-methyl-N-nitrosourea (MNU) in female SD arts   Ganoderma spore lipid (GSL)                                                                                                       500, 1000, 2000, and 4000 mg/kg                          Expressions of Bax, Bcl-xl, and caspase-3                                                                            Improve A-wave amplitude (*μ*v) decreased apoptosis levels          Regulate the expressions of Bax, Bcl-xl, and caspases-3, inhibiting MNU-induced rat, photoreceptor cell apoptosis, and protecting retinal function                                                                                                                         \[[@B30]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  4     A carotid-artery-ligation mouse model                                                  Ganoderma triterpenoid (GT)                                                                                                       300 mg/kg/day                                            Intimal hyperplasia structural changes VCAM-1, TNF-*α*, and IL-6                                                     Atheroprotective properties                                         Endothelin-1, von Willebrand factor, and monocyte chemoattractant protein-1                                                                                                                                                                                                \[[@B33]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  5     Swimming-induced oxidative stress in skeletal muscle mice                              GLPS                                                                                                                              50, 100, and 200 mg/kg                                   SOD, GPX, and CAT activities as well as by the MDA levels                                                            Attenuates exercise-induced oxidative stress in skeletal muscle     Increasing antioxidant enzyme activities and decrease the MDA levels. Protective effects against exhaustive exercise-induced oxidative stress                                                                                                                              \[[@B32]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  6     Rat gastric cancer model                                                               GLPS                                                                                                                              400-800 mg/kg for 20 weeks                               SOD, CAT, and GSH-Px                                                                                                 Antioxidant                                                         Induced the levels of serum IL-6 and TNF-*α* levels and increased the levels of serum IL-2, IL-4, and IL-10 in GLP-treated rats compared to gastric cancer model rats                                                                                                      \[[@B37]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  7     BALB/c female mice                                                                     GLPS i.p. daily                                                                                                                   50 mg/kg, 100 mg/kg, and 200 mg/kg                       SOD and GSH-Px                                                                                                       Antioxidant                                                         Improved immunity in mice. Increased thymus and spleen index; improved SOD and GSH-Px contents in the mice body                                                                                                                                                            \[[@B31]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  8     T2DM rats                                                                              GLPS                                                                                                                              200, 400, and 800 mg × kg^−1^ for 16 weeks               NO, SOD, MDA, GSH-Px, and CAT MDA in cardiac tissue                                                                  Antioxidation in cardiac tissue of T2DM rats                        Reduce MDA in cardiac tissue and improve the myocardial ultrastructure                                                                                                                                                                                                     \[[@B34]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  9     Male BALB/c mice (age19-21 months) (aged mice)                                         Ethanolic extract of *G*. *lucidum*                                                                                               50 and 250 mg/kg, once daily for 15 days                 GSH Mn-SOD, GPx, and GST                                                                                             Antioxidant in heart tissues                                        Elevated the levels of GSH as well as activities of MnSOD, GPx, and GST and decreased significantly the levels of lipid peroxidation, AOPP, and ROS. Improve the age-related decline of antioxidant status which was partly ascribed to free radical scavenging activity   \[[@B38]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  10    B16 mouse melanoma                                                                     Methanol extract containing total terpenoids (GLme) and a purified methanol extract containing mainly acidic terpenoids (GLpme)   A daily i.p. injection of 100 mg/kg body weight (b.w.)   Production of oxygen radical caspase-dependent apoptotic cell death-mediated production of reactive oxygen species   Anticancer                                                          The mechanism of antitumor activity of GLme comprised inhibition of cell proliferation and induction of caspase-dependent apoptotic cell death mediated by upregulated p53 and inhibited Bcl-2 expression                                                                  \[[@B86]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  11    With non-insulin-dependent diabetes mellitus (NIDDM)                                   Ganoderma *lucidum* spores                                                                                                        250 mg/kg × d, for 10                                    Xanthine oxidase (XOD), myeloperoxidase (MPO), and mitochondrial succinate dehydrogenase (SDH) in the testis         Reducing free radical-induceddamage to the testicular tissue        Protect the testis of diabetic rats by reducing free radical-induced damage to the testicular tissue and enhancing the activity of SDH                                                                                                                                     \[[@B35]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  12    Epididymal cells of type 2 diabetes rats                                               *Ganoderma lucidum* spores (GLS)                                                                                                  250 mg/kg × d, for 10 weeks                              Contents of mitochondrial calcium & cytochrome C                                                                     Antipoptosis induced by DM                                          Protect epididymal cells and counteract their apoptosis in diabetic condition                                                                                                                                                                                              \[[@B36]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  13    Liver tissue of rats                                                                   *Ganoderma lucidum* peptide                                                                                                       27.1 *μ*g/mL                                             Malondialdehyde level                                                                                                Antioxidant                                                         Substantial antioxidant activity in the rat liver tissue homogenates and mitochondrial membrane peroxidation systems                                                                                                                                                       \[[@B87]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  14    Lupus mice                                                                             Ganoderma tsugae                                                                                                                  0.5 mg/kg/day                                            Decreased proteinuria, decreased serum levels of antidsDNA autoantibody                                              Prevention of autoantibody                                          Prevention of autoantibody formation                                                                                                                                                                                                                                       \[[@B88]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

*In vitro* studies of *G. lucidum.*

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Form                                              Conc.                                                 Chemical antioxidant tests   Biological text of in vitro                       Exp. parameters                                    Biological activity                                               Pathway                                                                                                                                                       References
  ----- ------------------------------------------------- ----------------------------------------------------- ---------------------------- ------------------------------------------------- -------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  1     GLP                                               0.5-3.0 mg/mL                                         RS\                          =                                                 Scavenging of free radicals and reducing power     Antioxidant                                                       NM                                                                                                                                                            \[[@B89]\]
                                                                                                                FR                                                                                                                                                                                                                                                                                                                                                                

  2     *G*. *lucidum* and Egyptian Chlorella vulgaris    CVE (63.5 *μ*g/mL) was mixed with GLE (4.1 *μ*g/mL)   RS\                          Lipopolysaccharide-stimulated white blood cells   Nitric oxide, tumor necrosis factor- (TNF-) *α*    Antioxidant and anti-inflammatory                                 Downregulate NF-*κ*B                                                                                                                                          \[[@B39]\]
                                                                                                                FR\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                AP\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  3     Polysaccharides in *G*. *lucidum*                 2 mg/mL                                               RS\                          NM                                                Radical scavenging reducing power                  Antioxidant                                                       NM                                                                                                                                                            \[[@B90]\]
                                                                                                                FR\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                AP\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  4     *G*. *lucidum* extract                            50 mg                                                 RS\                          NM                                                Reducing power                                     Antimicrobial and antioxidant                                     NM                                                                                                                                                            \[[@B40]\]
                                                                                                                FR\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                AP\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  5     *Ganoderma lucidum* G2                            0.32 mg                                               RS\                          DNA protection                                    Radical scavenging reducing power                  Antimicrobial and antioxidant                                     NM                                                                                                                                                            \[[@B41]\]
                                                                                                                FR\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                AP\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  6     Protein extracts                                  2--13 *μ*g protein/mL                                 AP\                          DNA protection                                    Radical scavenging reducing power                  Antioxidant, antibacterial                                        NM                                                                                                                                                            \[[@B42]\]
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  7     Polysaccharides extraction                        =                                                     FR\                          MCF-7 breast cancer cell line and HeLa cells      Radical scavenging                                 Antioxidant\                                                      NM                                                                                                                                                            \[[@B43]\]
                                                                                                                AP\                                                                                                                               Anticancer                                                                                                                                                                                                                      
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  8     *G*. *lucidum* and G. resinaceum                  0.1--1 & 0.64 ± 0.04\                                 FR\                          In vitro cell line                                Radical-scavenging chelating lipoxygenase assay    Antiproliferative & antioxidant                                   NM                                                                                                                                                            \[[@B44]\]
                                                          0--2.25 mg/mL                                         AP\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  9     Diff, organic solvent o *G*. *lucidum*            1-200 *μ*g/mL                                         FR\                          NM                                                Radical scavenging, chelating lipid peroxidation   Antioxidant\                                                      NM                                                                                                                                                            \[[@B45]\]
                                                                                                                AP\                                                                                                                               Anticholinesterase                                                                                                                                                                                                              
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  10    Both aqueous and methanolic extracts              0.2--30 mg/mL of extraction                           FR\                          NM                                                Radical scavenging, chelating lipid peroxidation   Antioxidant                                                       NM                                                                                                                                                            \[[@B46]\]
                                                                                                                AP\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  11    Low-molecular-weight *β*-1,3-glucan               0--200 *μ*g/mL                                        AP\                          Mouse monocyte-macrophage cell line, RAW 264.7    H~2~O~2~-induced apoptosis                         Antioxidant                                                       Attenuating intracellular reactive oxygen species (ROS) and inhibiting sphingomyelinase (SMase) activity                                                      \[[@B51]\]
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  12    Polysaccharides                                   0.16-10 mg/mL                                         FR\                          NM                                                Radical scavenging, chelating reducing power       Antioxidant                                                       NM                                                                                                                                                            \[[@B47]\]
                                                                                                                AP\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  13    *G*. *lucidum*water-soluble and water-insoluble   80-1100 *μ*g/ml                                       FR\                          Human uroepithelial cell (HUC-PC) cells           Radical scavenging, chelating reducing power       Antioxidant                                                       Oxidative DNA damage. Lingzhi-induced apoptosis in bladder chemoprevention                                                                                    \[[@B48]\]
                                                                                                                AP\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                Other tests                                                                                                                                                                                                                                                                                                                                                       

  14    *Ganoderma lucidum* polysaccharides               0.1-0.6 mg/ml                                         RS                           CCl-induced injury hepatocytes DNA protection     MDA, SOD, CYP3A, caspase-3, andcaspase-8           Suppressing inflammatory responses                                Reduction of NF-*κ*B activation inhibition of caspase-3, caspase-6, and caspase-9, indicating and suppression extrinsic-induced apoptosis                     \[[@B52]\]

  15    Ganoderic acid A                                  10-80 lM/mL                                           NM                           Pancreatic cells                                  Radical scavenging\                                Antioxidant\                                                      *β*-Catenin in Wnt signaling pathway                                                                                                                          \[[@B54]\]
                                                                                                                                                                                               Antiproliferative                                  Anticancer                                                                                                                                                                                                                      

  16    Aqueous extract of *G*. *lucidum*                 5-20 *μ*L                                             NM                           DNA protection                                    Radical scavenging                                 Antioxidant\                                                      Enhancing reactivity of apurinic/apyrimidinic endonucleases (APE1) a major enzyme of base excision repair (BER)                                               \[[@B91]\]
                                                                                                                                                                                                                                                  DNA repair                                                                                                                                                                                                                      

  17    Methanolic extract of *G*. *lucidum*              65 & 130 *μ*g/mL                                      NM                           Human gastric tumor cells                         Increased the formation of autophagosomes          Induces autophagy                                                 Increasing of the cellular levels of LC3-II and decreasing p62 (autophagy-related protein)                                                                    \[[@B92]\]

  18    *G*. *lucidum* (GLPS) and G. sinense (GSPS)       19--300 *μ*g/mL                                       NM                           RAW 264.7 mouse macrophage cells                  Nitric oxide secretion of cytokines                Immunomodulatory                                                  Promoting macrophage phagocytosis, increasing their release of nitric oxide and cytokines interleukin- (IL-) 1a, IL-6, IL-10, and tumor necrosis factor-*α*   \[[@B56]\]

  19    Proteopolysaccharide from *G*. *lucidum*          2 - 10 *μ*g/mL                                        NM                           RAW264.7, a mouse macrophage cell line            Nitrite production\                                Activation the immune system by modulating cytokine production.   NM                                                                                                                                                            \[[@B57]\]
                                                                                                                                                                                               Expression levels of cytokines                                                                                                                                                                                                                                                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NM = not mention; RS = radical scavenging; FR = ferric reducing; AP = antilipid peroxidation.
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